Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities
September 12, 2025 / obesity genetics / cardiometabolic risk / precision medicine / genome-wide association / fat distribution
Researchers identified 266 genetic variants that increase body fat but lower cardiometabolic risk, revealing eight genetic subtypes of obesity. This uncoupling provides new insights into obesity biology and supports precision medicine approaches for cardiometabolic disease prevention and treatment.
Gut Bacteria Therapy Reduces Metabolic Syndrome in Obese Teens
September 9, 2025 / gut microbiome / metabolic syndrome / fecal transplant / adolescent obesity / diabetes prevention
A single fecal microbiota transfer in obese teens led to long-term metabolic benefits, significantly reducing risk factors for conditions like heart disease and diabetes, according to an 8-year study published in Nature Communications.
Bariatric Surgery Reduces Metabolic Comorbidities in Patients With Obesity
September 9, 2025 / bariatric surgery / metabolic comorbidities / obesity treatment / diabetes prevention / weight loss
A large VHA study found that bariatric surgery significantly reduces the risk of five major obesity-related metabolic comorbidities—hypertension, diabetes, hyperlipidemia, OSA, and MASLD—compared to lifestyle and medical weight management programs.
Female-specific mechanism enhances heat production in brown fat
September 12, 2025 / PGC-1α / brown fat / female metabolism / obesity prevention / energy expenditure
A Japanese study found that PGC-1α enhances brown fat thermogenesis in female mice by promoting mitochondrial phospholipid synthesis, revealing a female-specific mechanism in energy metabolism that could inform new obesity and diabetes therapies.
Aphaia doses first subject in second Phase II obesity treatment trial
September 10, 2024 / GLP-1 / obesity treatment / Aphaia Pharma / L-cell hormones / weight loss therapy
Aphaia Pharma has begun dosing in a second Phase II trial for its oral, glucose-based obesity treatment, which stimulates L-cell hormone release (including GLP-1) to enhance weight loss and metabolic outcomes with minimal side effects.
New Clinical Trials Confirm That Increased Semaglutide Dosages Safely Boost Weight Loss and Health Benefits in Adults with Obesity
September 15, 2025 / Semaglutide / Obesity Treatment / Weight Loss Drug / Type 2 Diabetes / Clinical Trial Results
Phase 3 trials show 7.2 mg semaglutide significantly improves weight loss and metabolic outcomes in adults with obesity—both with and without T2D—while maintaining a favorable safety profile, outperforming the standard 2.4 mg dose.
Adding PYY1875 to Semaglutide Yields Limited Weight Loss Gains in Obesity Study
September 12, 2025 / PYY1875 / Semaglutide / Obesity Treatment / Weight Loss Study / Gut Hormone Therapy
Adding PYY1875 to semaglutide resulted in only modest additional weight loss and notable gastrointestinal side effects, limiting its utility as a combination therapy for obesity despite promising preclinical outcomes.
Scientists Unveil Potential First-of-Its-Kind Treatment for Deadly Fatty Liver Disease
September 13, 2025 / MASH Treatment / Fatty Liver Disease / ION224 Drug / DGAT2 Inhibitor / Obesity and Liver Health
ION224, a DGAT2 inhibitor, showed promising Phase IIb results by reducing liver fat and inflammation in MASH patients, offering a potential first-in-class targeted therapy with no serious side effects, independent of weight loss.
Scientists discover new clues about joint disease and possible treatments
September 9, 2025 / Osteoarthritis / Joint Degeneration / SIRT5 Protein / Cartilage Health / Obesity and Aging
Researchers identified the protein SIRT5 as a key regulator in cartilage metabolism, revealing its potential role in osteoarthritis progression and offering a new target for therapies aimed at slowing or reversing joint degeneration linked to aging and obesity.
Green tea improves insulin sensitivity and glucose tolerance in obese mice
September 10, 2024 / Green Tea / Obesity Treatment / Insulin Sensitivity / Glucose Metabolism / Adiponectin Pathway
Green tea extract improved insulin sensitivity, glucose metabolism, and preserved muscle morphology in obese mice, likely through adiponectin-mediated pathways—highlighting its potential as an adjunct treatment for obesity and type 2 diabetes.
Neuritin 1 Could Be a New Target for Obesity Therapy
September 10, 2025 / Neuritin 1 / Obesity Treatment / Brown Fat Metabolism / Thermogenesis / Type 2 Diabetes
Neuritin 1 enhances brown fat thermogenesis and improves metabolic health without reducing food intake, positioning it as a novel therapeutic target for obesity, type 2 diabetes, and fatty liver disease via non-appetite-suppressing pathways.
High BMI and obesity may not always increase mortality risk
September 15, 2025 / BMI and Mortality / Obesity Risk / Fat but Fit / Overweight Health Outcomes / EASD Study
A large Danish study found that individuals with overweight or mild obesity had similar or lower mortality risk than those with lower-normal or underweight BMI, suggesting that BMI alone may not fully predict health outcomes.
Review Reveals the Hidden Burden of Psoriasis on Children, Families
September 15, 2025 / Pediatric Psoriasis / Childhood Skin Disease / Psoriasis Burden / Family Impact / Quality of Life
Systematic reviews reveal that moderate to severe pediatric psoriasis causes significant physical, emotional, and economic burdens on children and families, yet economic data are scarce—highlighting the urgent need for comprehensive research to guide treatment and resource planning.
Gut Microbiome: Defensin Genes Protect From Metabolic Diseases
September 12, 2025 / Gut Microbiome / Defensin Genes / Insulin Resistance / Obesity Prevention / Precision Medicine
University of Sydney researchers identified defensin genes—especially Defa26—as key regulators of gut microbiome and metabolic health, revealing that genetic variation influences insulin sensitivity and obesity risk, underscoring the need for personalized approaches in microbiome-targeted therapies.
Ketogenic diets may lower migraine frequency and medication use
September 14, 2025 / Ketogenic Diet / Migraine Relief / Metabolic Dysfunction / Mitochondrial Health / Chronic Headaches
Ketogenic diets may reduce migraine frequency, intensity, and medication use by improving cerebral metabolism and correcting mitochondrial dysfunction. Though promising, more standardized, large-scale trials are needed to confirm safety and efficacy across patient populations.
Keto diet reduces depression symptoms by 70% in college students
September 15, 2025 / Ketogenic Diet / Depression Treatment / Mental Health Nutrition / College Students / Nutritional Psychiatry
A 10–12 week ketogenic diet intervention reduced depression symptoms by 70% in college students already receiving counseling, likely through metabolic, anti-inflammatory, and neurochemical pathways—supporting its potential as an adjunctive treatment for major depression.
Genetic study shows dual GIPR/GLP1R action curbs binge alcohol use
September 15, 2025 / GLP1R Agonist / GIPR Therapy / Alcohol Use Disorder / Binge Drinking Reduction / Metabolic Drug Repurposing
Genetic analysis shows dual GIPR/GLP1R agonism may reduce binge alcohol use and related liver outcomes, suggesting potential repurposing of metabolic drugs like GLP-1-based therapies for treating alcohol use disorder and broader substance-related behaviors.
5 simple ways to prime your microbiome for easier weight loss
September 12, 2025 / Gut Microbiome / Personalized Nutrition / Weight Loss Strategy / Cardiometabolic Health / Microbiome Testing
Targeting the gut microbiome through personalized diets can enhance weight loss and improve cardiometabolic health. Studies like PREDICT show that aligning dietary interventions with individual microbiome profiles leads to better outcomes than standard diet advice.
Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
September 16, 2025 / siRNA Therapy / Obesity Treatment / INHBE Targeting / RNAi Therapeutics / Fat Metabolism
Rona Therapeutics’ RN3161, a GalNAc-conjugated siRNA targeting INHBE, shows over 90% gene silencing in preclinical studies and may reduce fat while preserving lean mass, offering a durable, low-dose RNAi treatment for obesity with improved safety and adherence.
FDA weighs noninvasive biopsy alternative in MASH clinical trials
September 15, 2025 / MASH Clinical Trials / Fibroscan FDA / Noninvasive Liver Test / Liver Fibrosis Monitoring / Fatty Liver Disease
The FDA is evaluating Fibroscan, a noninvasive ultrasound-based tool, as a potential surrogate endpoint to replace liver biopsies in MASH clinical trials—potentially accelerating drug development while reducing patient burden and improving trial accessibility.